Switch to:
Also traded in: Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 0.41
RHHBY's Cash-to-Debt is ranked lower than
71% of the 799 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.05 vs. RHHBY: 0.41 )
Ranked among companies with meaningful Cash-to-Debt only.
RHHBY' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.36  Med: 1.18 Max: N/A
Current: 0.41
Equity-to-Asset 0.31
RHHBY's Equity-to-Asset is ranked lower than
87% of the 731 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.64 vs. RHHBY: 0.31 )
Ranked among companies with meaningful Equity-to-Asset only.
RHHBY' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.1  Med: 0.38 Max: 0.59
Current: 0.31
0.1
0.59
Interest Coverage 20.45
RHHBY's Interest Coverage is ranked lower than
65% of the 632 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 112.31 vs. RHHBY: 20.45 )
Ranked among companies with meaningful Interest Coverage only.
RHHBY' s Interest Coverage Range Over the Past 10 Years
Min: 5.94  Med: 12.43 Max: N/A
Current: 20.45
Piotroski F-Score: 9
Altman Z-Score: 3.70
Beneish M-Score: -2.75
WACC vs ROIC
5.02%
27.14%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 27.82
RHHBY's Operating Margin % is ranked higher than
91% of the 758 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.95 vs. RHHBY: 27.82 )
Ranked among companies with meaningful Operating Margin % only.
RHHBY' s Operating Margin % Range Over the Past 10 Years
Min: 25.03  Med: 28.89 Max: 33.69
Current: 27.82
25.03
33.69
Net Margin % 18.93
RHHBY's Net Margin % is ranked higher than
84% of the 759 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.06 vs. RHHBY: 18.93 )
Ranked among companies with meaningful Net Margin % only.
RHHBY' s Net Margin % Range Over the Past 10 Years
Min: 15.87  Med: 18.83 Max: 22.97
Current: 18.93
15.87
22.97
ROE % 45.35
RHHBY's ROE % is ranked higher than
95% of the 780 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.91 vs. RHHBY: 45.35 )
Ranked among companies with meaningful ROE % only.
RHHBY' s ROE % Range Over the Past 10 Years
Min: 19.94  Med: 45.85 Max: 102.95
Current: 45.35
19.94
102.95
ROA % 12.65
RHHBY's ROA % is ranked higher than
84% of the 805 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.71 vs. RHHBY: 12.65 )
Ranked among companies with meaningful ROA % only.
RHHBY' s ROA % Range Over the Past 10 Years
Min: 10.33  Med: 12.78 Max: 17.58
Current: 12.65
10.33
17.58
ROC (Joel Greenblatt) % 62.96
RHHBY's ROC (Joel Greenblatt) % is ranked higher than
87% of the 793 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 13.48 vs. RHHBY: 62.96 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
RHHBY' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 52.39  Med: 64.84 Max: 84.52
Current: 62.96
52.39
84.52
3-Year Revenue Growth Rate 1.40
RHHBY's 3-Year Revenue Growth Rate is ranked lower than
64% of the 634 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.10 vs. RHHBY: 1.40 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
RHHBY' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -3.5  Med: 5.2 Max: 394
Current: 1.4
-3.5
394
3-Year EBITDA Growth Rate -2.20
RHHBY's 3-Year EBITDA Growth Rate is ranked lower than
70% of the 601 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.90 vs. RHHBY: -2.20 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
RHHBY' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -2.2  Med: 9.35 Max: 271.3
Current: -2.2
-2.2
271.3
3-Year EPS without NRI Growth Rate -4.90
RHHBY's 3-Year EPS without NRI Growth Rate is ranked lower than
68% of the 576 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.60 vs. RHHBY: -4.90 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
RHHBY' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -4.9  Med: 5.8 Max: 340.9
Current: -4.9
-4.9
340.9
GuruFocus has detected 6 Warning Signs with Roche Holding AG $RHHBY.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» RHHBY's 30-Y Financials

Financials (Next Earnings Date: 2018-02-01 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

RHHBY Guru Trades in Q3 2016

Mairs and Power 4,644,431 sh (+15.95%)
Ken Fisher 15,126,928 sh (-0.10%)
» More
Q4 2016

RHHBY Guru Trades in Q4 2016

Mairs and Power 4,982,597 sh (+7.28%)
Ken Fisher 14,946,458 sh (-1.19%)
» More
Q1 2017

RHHBY Guru Trades in Q1 2017

Mairs and Power 5,067,407 sh (+1.70%)
Ken Fisher 15,104,940 sh (+1.06%)
» More
Q2 2017

RHHBY Guru Trades in Q2 2017

Ken Fisher 11,875,382 sh (-21.38%)
» More
» Details

Insider Trades

Latest Guru Trades with RHHBY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major    NAICS: 325412    SIC: 2834
Compare:XSWX:NOVN » details
Traded in other countries:RHO5.Germany, ROG N.Mexico, RO.Switzerland, 0QOK.UK,
Headquarter Location:Switzerland
Roche Holding AG is a pharmaceutical and diagnostic company. It specializes in medicines for oncology, virology, inflammation, metabolism, clinical chemistry, immunology, urinalysis, blood screening, genetics, infectious diseases, and microbiology.

Roche is a Swiss biopharmaceutical and diagnostic company. The firm's best-selling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for more than 60% of pharmaceutical sales, and professional diagnostics for more than half of diagnostic-related sales.

Top Ranked Articles about Roche Holding AG

Roche gains CE label expansion for companion diagnostic to identify ALK-positive non-small cell lung cancer patients
The Klein Law Firm Reminds Investors of a Class Action Filed on Behalf of Roche Holding AG Shareholders and a Lead Plaintiff Deadline of August 7, 2017 (RHHBY)
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Roche Holding AG - RHHBY
RHHBY SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Roche Holding AG and a Lead Plaintiff Deadline of August 7, 2017
Roche receives FDA approval for fourth-generation HIV combination antigen-antibody assay --allowing detection of infection with high sensitivity and specificity
ROCHE LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Roche Holding AG To Contact The Firm
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Roche Holding AG - RHHBY
IMPORTANT EQUITY ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Roche Holding AG and Encourages Investors with Losses to Contact the Firm
SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Roche Holding AG. (RHHBY) & Lead Plaintiff Deadline: August 7, 2017
IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces a Securities Class Action Lawsuit against Roche Holding AG and Encourages Investors with Losses to Contact the Firm

Ratios

vs
industry
vs
history
PE Ratio 21.67
RHHBY's PE Ratio is ranked higher than
62% of the 555 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 26.93 vs. RHHBY: 21.67 )
Ranked among companies with meaningful PE Ratio only.
RHHBY' s PE Ratio Range Over the Past 10 Years
Min: 0.13  Med: 15.4 Max: 26.92
Current: 21.67
0.13
26.92
Forward PE Ratio 15.82
RHHBY's Forward PE Ratio is ranked higher than
66% of the 67 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 18.90 vs. RHHBY: 15.82 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 21.67
RHHBY's PE Ratio without NRI is ranked higher than
63% of the 554 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.21 vs. RHHBY: 21.67 )
Ranked among companies with meaningful PE Ratio without NRI only.
RHHBY' s PE Ratio without NRI Range Over the Past 10 Years
Min: 0.13  Med: 15.4 Max: 26.92
Current: 21.67
0.13
26.92
Price-to-Owner-Earnings 15.92
RHHBY's Price-to-Owner-Earnings is ranked higher than
78% of the 303 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 32.90 vs. RHHBY: 15.92 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
RHHBY' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 0.09  Med: 14.06 Max: 19.34
Current: 15.92
0.09
19.34
PB Ratio 8.58
RHHBY's PB Ratio is ranked lower than
89% of the 751 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.80 vs. RHHBY: 8.58 )
Ranked among companies with meaningful PB Ratio only.
RHHBY' s PB Ratio Range Over the Past 10 Years
Min: 0.03  Med: 9.79 Max: 14.85
Current: 8.58
0.03
14.85
PS Ratio 4.10
RHHBY's PS Ratio is ranked lower than
62% of the 736 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.97 vs. RHHBY: 4.10 )
Ranked among companies with meaningful PS Ratio only.
RHHBY' s PS Ratio Range Over the Past 10 Years
Min: 0.02  Med: 3.33 Max: 5.04
Current: 4.1
0.02
5.04
Price-to-Free-Cash-Flow 20.72
RHHBY's Price-to-Free-Cash-Flow is ranked higher than
60% of the 208 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 25.89 vs. RHHBY: 20.72 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
RHHBY' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 0.09  Med: 13.08 Max: 23.2
Current: 20.72
0.09
23.2
Price-to-Operating-Cash-Flow 13.83
RHHBY's Price-to-Operating-Cash-Flow is ranked higher than
64% of the 277 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.02 vs. RHHBY: 13.83 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
RHHBY' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 0.07  Med: 10.88 Max: 15.66
Current: 13.83
0.07
15.66
EV-to-EBIT 16.12
RHHBY's EV-to-EBIT is ranked higher than
64% of the 559 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 20.11 vs. RHHBY: 16.12 )
Ranked among companies with meaningful EV-to-EBIT only.
RHHBY' s EV-to-EBIT Range Over the Past 10 Years
Min: -0.6  Med: 11.9 Max: 19.8
Current: 16.12
-0.6
19.8
EV-to-EBITDA 12.45
RHHBY's EV-to-EBITDA is ranked higher than
66% of the 587 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.50 vs. RHHBY: 12.45 )
Ranked among companies with meaningful EV-to-EBITDA only.
RHHBY' s EV-to-EBITDA Range Over the Past 10 Years
Min: -0.5  Med: 10.1 Max: 15.7
Current: 12.45
-0.5
15.7
PEG Ratio 20.00
RHHBY's PEG Ratio is ranked lower than
94% of the 313 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.94 vs. RHHBY: 20.00 )
Ranked among companies with meaningful PEG Ratio only.
RHHBY' s PEG Ratio Range Over the Past 10 Years
Min: 0.01  Med: 3.53 Max: 23.21
Current: 20
0.01
23.21
Shiller PE Ratio 20.81
RHHBY's Shiller PE Ratio is ranked higher than
79% of the 198 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 39.37 vs. RHHBY: 20.81 )
Ranked among companies with meaningful Shiller PE Ratio only.
RHHBY' s Shiller PE Ratio Range Over the Past 10 Years
Min: 0.18  Med: 21.73 Max: 26.32
Current: 20.81
0.18
26.32
Current Ratio 1.27
RHHBY's Current Ratio is ranked lower than
81% of the 782 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.40 vs. RHHBY: 1.27 )
Ranked among companies with meaningful Current Ratio only.
RHHBY' s Current Ratio Range Over the Past 10 Years
Min: 1.19  Med: 2.33 Max: 3.75
Current: 1.27
1.19
3.75
Quick Ratio 0.92
RHHBY's Quick Ratio is ranked lower than
79% of the 782 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.82 vs. RHHBY: 0.92 )
Ranked among companies with meaningful Quick Ratio only.
RHHBY' s Quick Ratio Range Over the Past 10 Years
Min: 0.86  Med: 1.93 Max: 3.22
Current: 0.92
0.86
3.22
Days Inventory 178.94
RHHBY's Days Inventory is ranked lower than
78% of the 707 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 117.36 vs. RHHBY: 178.94 )
Ranked among companies with meaningful Days Inventory only.
RHHBY' s Days Inventory Range Over the Past 10 Years
Min: 143.33  Med: 159.24 Max: 186.16
Current: 178.94
143.33
186.16
Days Sales Outstanding 63.22
RHHBY's Days Sales Outstanding is ranked higher than
60% of the 651 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 74.70 vs. RHHBY: 63.22 )
Ranked among companies with meaningful Days Sales Outstanding only.
RHHBY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 63.14  Med: 73.14 Max: 84.09
Current: 63.22
63.14
84.09
Days Payable 76.14
RHHBY's Days Payable is ranked higher than
53% of the 600 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 70.96 vs. RHHBY: 76.14 )
Ranked among companies with meaningful Days Payable only.
RHHBY' s Days Payable Range Over the Past 10 Years
Min: 49.43  Med: 60.53 Max: 78.64
Current: 76.14
49.43
78.64

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 3.21
RHHBY's Dividend Yield % is ranked higher than
85% of the 691 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.23 vs. RHHBY: 3.21 )
Ranked among companies with meaningful Dividend Yield % only.
RHHBY' s Dividend Yield % Range Over the Past 10 Years
Min: 0.03  Med: 2.83 Max: 4.55
Current: 3.21
0.03
4.55
Dividend Payout Ratio 0.73
RHHBY's Dividend Payout Ratio is ranked lower than
84% of the 406 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.33 vs. RHHBY: 0.73 )
Ranked among companies with meaningful Dividend Payout Ratio only.
RHHBY' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0  Med: 0.29 Max: 0.78
Current: 0.73
0
0.78
3-Year Dividend Growth Rate 3.30
RHHBY's 3-Year Dividend Growth Rate is ranked lower than
59% of the 299 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.90 vs. RHHBY: 3.30 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
RHHBY' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: -75.5  Med: 21.05 Max: 414.3
Current: 3.3
-75.5
414.3
Forward Dividend Yield % 3.20
RHHBY's Forward Dividend Yield % is ranked higher than
82% of the 673 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.60 vs. RHHBY: 3.20 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 107.69
RHHBY's 5-Year Yield-on-Cost % is ranked higher than
100% of the 821 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.11 vs. RHHBY: 107.69 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
RHHBY' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 1.01  Med: 94.94 Max: 152.65
Current: 107.69
1.01
152.65
3-Year Average Share Buyback Ratio -0.10
RHHBY's 3-Year Average Share Buyback Ratio is ranked higher than
82% of the 473 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.10 vs. RHHBY: -0.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
RHHBY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -169.8  Med: 0.25 Max: 78.7
Current: -0.1
-169.8
78.7

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 353.33
RHHBY's Price-to-Tangible-Book is ranked lower than
99% of the 690 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.51 vs. RHHBY: 353.33 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
RHHBY' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.04  Med: 0.86 Max: 357.75
Current: 353.33
0.04
357.75
Price-to-Intrinsic-Value-Projected-FCF 1.59
RHHBY's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
64% of the 328 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.31 vs. RHHBY: 1.59 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
RHHBY' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.01  Med: 0.04 Max: 1.83
Current: 1.59
0.01
1.83
Price-to-Median-PS-Value 1.23
RHHBY's Price-to-Median-PS-Value is ranked lower than
63% of the 712 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.09 vs. RHHBY: 1.23 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
RHHBY' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.01  Med: 0.02 Max: 2.55
Current: 1.23
0.01
2.55
Price-to-Graham-Number 18.38
RHHBY's Price-to-Graham-Number is ranked lower than
99% of the 480 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.08 vs. RHHBY: 18.38 )
Ranked among companies with meaningful Price-to-Graham-Number only.
RHHBY' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.02  Med: 0.13 Max: 18.69
Current: 18.38
0.02
18.69
Earnings Yield (Greenblatt) % 6.22
RHHBY's Earnings Yield (Greenblatt) % is ranked higher than
75% of the 805 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.10 vs. RHHBY: 6.22 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
RHHBY' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -247.6  Med: 6 Max: 60
Current: 6.22
-247.6
60
Forward Rate of Return (Yacktman) % 6.60
RHHBY's Forward Rate of Return (Yacktman) % is ranked lower than
58% of the 380 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.46 vs. RHHBY: 6.60 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
RHHBY' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 4.3  Med: 8.8 Max: 790.9
Current: 6.6
4.3
790.9

More Statistics

Revenue (TTM) (Mil) $50,876.87
EPS (TTM) $ 1.40
Beta0.52
Short Percentage of Float0.00%
52-Week Range $25.25 - 36.82
Shares Outstanding (Mil)6,815.42 (ADR)

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 56,127 59,837 65,646
EPS ($) 2.01 2.19 2.41
EPS without NRI ($) 2.01 2.19 2.41
EPS Growth Rate
(Future 3Y To 5Y Estimate)
7.70%
Dividends per Share ($) 1.09 1.14 1.23
» More Articles for RHHBY

Headlines

Articles On GuruFocus.com
Roche gains CE label expansion for companion diagnostic to identify ALK-positive non-small cell lung Jul 25 2017 
The Klein Law Firm Reminds Investors of a Class Action Filed on Behalf of Roche Holding AG Sharehold Jul 17 2017 
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Roche Holdi Jul 14 2017 
RHHBY SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involvi Jul 14 2017 
Roche receives FDA approval for fourth-generation HIV combination antigen-antibody assay --allowing Jun 23 2017 
Seeking Value in Biotech: Biogen Jun 22 2017 
ROCHE LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses E Jun 14 2017 
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Roche Holding AG Jun 13 2017 
IMPORTANT EQUITY ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Roche Holdin Jun 12 2017 
SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Ro Jun 12 2017 

More From Other Websites
Roche gains CE label expansion for companion diagnostic to identify ALK-positive non-small cell lung... Jul 25 2017
TWO WEEK DEADLINE: Lundin Law PC Announces Securities Class Action Lawsuit against Roche Holding AG... Jul 24 2017
IMMINENT ROCHE LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered... Jul 24 2017
The Klein Law Firm Reminds Investors of a Class Action Filed on Behalf of Roche Holding AG... Jul 24 2017
DEADLINE APPROACHING: Khang & Khang LLP Announces Securities Class Action Lawsuit against Roche... Jul 21 2017
RHHBY INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving... Jul 21 2017
5 New Breast Cancer Treatments That Are Helping to Save Lives Jul 20 2017
DEADLINE ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Roche Holding AG and... Jul 20 2017
EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Roche Holding AG of a Class Action... Jul 20 2017
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against... Jul 20 2017
SHAREHOLDER REMINDER: Khang & Khang LLP Announces Securities Class Action Lawsuit against Roche... Jul 19 2017
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Roche Holding AG of a Class Action... Jul 19 2017
Poor test results for Roche cloud growth prospects Jul 19 2017
These 2 Drug Giants In Buy Range Just Beat Earnings Views Jul 18 2017
DEADLINE APPROACHING: Lundin Law PC Announces Securities Class Action Lawsuit against Roche Holding... Jul 18 2017
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Roche Holding AG of a Class Action... Jul 18 2017
The Zacks Analyst Blog Highlights: Infosys, Toyota Motor, Honda Motor, Taiwan Semiconductor... Jul 18 2017
UPCOMING DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Roche Holding... Jul 17 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}